Pharma Focus Asia

Zhejiang Doer Biologics Announces Licence Agreement with BioNTech

Tuesday, July 11, 2023

Zhejiang Doer Biologics has entered into a licence agreement with BioNTech. The agreement grants BioNTech a worldwide licence to utilise one of Doer Bio's innovative discoveries for the research, development, manufacturing, and commercialisation of biotherapeutics. 

As part of the agreement, Doer Bio will receive an upfront payment from BioNTech and will also be eligible for potential milestone payments related to development, regulatory approval, and commercialisation.

This partnership with BioNTech is seen as a significant validation of Doer Bio's platform technologies, which have undergone extensive preclinical research and ongoing clinical studies. The collaboration between the two companies aims to translate Doer Bio's technologies and discoveries into novel therapies that can ultimately benefit patients worldwide.

This licence agreement represents an exciting opportunity for both Doer Bio and BioNTech to combine their expertise and resources to advance innovative biotherapeutics and make a positive impact on global healthcare.

magazine-slider-imageCytiva - Supor Prime filtersMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Advanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024